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Abstract
Background: Parkinson’s disease (PD) is characterized by alterations in dopaminergic neurotransmission. Genetic
polymorphisms involved in dopaminergic neurotransmission may influence susceptibility to PD.
Methods: We investigated the relationship of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB),
dopamine receptor (DR) D2 and DRD4 polymorphisms and PD risk with special attention to the interaction with
cigarette smoking among 238 patients with PD and 369 controls in a Japanese population.
Results: Subjects with the AA genotype of MAOB rs1799836 showed a significantly increased risk of PD (odds ratio
(OR) = 1.70, 95% confidence interval (CI) = 1.12 - 2.58) compared with the AG and GG genotypes combined. The
AA genotype of COMT rs4680 was marginally associated with an increased risk of PD (OR = 1.86, 95% CI = 0.98 -
3.50) compared with the GG genotype. The DRD2 rs1800497 and DRD4 rs1800955 polymorphisms showed no
association with PD. A COMT -smoking interaction was suggested, with the combined GA and AA genotypes of
rs4680 and non-smoking conferring significantly higher risk (OR = 3.97, 95% CI = 2.13 - 7.41) than the AA genotype
and a history of smoking (P for interaction = 0.061). No interactions of smoking with other polymorphisms were
observed.
Conclusions: The COMT rs4680 and MAOB rs1799836 polymorphisms may increase susceptibility to PD risk among
Japanese. Future studies involving larger control and case populations and better pesticide exposure histories will
undoubtedly lead to a more thorough understanding of the role of the polymorphisms involved in the dopamine
pathway in PD.
Background
Dopamine is one of the major modulatory neurotrans-
mitters in the central nervous system (CNS) [1]. As dys-
function of dopaminergic neurotransmission in the CNS
has been implicated in development of PD [2], it has
been suggested that genetic polymorphisms involved in
the biosynthesis and degradation of dopamine and
related compounds influence susceptibility to PD. Cate-
chol-O-methyltransferase (COMT) is an enzyme, which
by methylation inactivates neurotransmitters and toxic
catechols such as the immediate precursor of dopamine.
Monoamine oxidase B (MAOB) is one of the primary
enzymes regulating metabolism of neurotransmitters
such as dopamine. There are five known dopamine
receptors (DRD1-5) grouped into D-1 like (DRD1 and
DRD5) and D-2 like (DRD2, DRD3 and DRD4) recep-
tors based on their pharmacological profiles and
sequence homology. Of these, DRD2 and DRD4 govern
the signaling effect and modulate the motor behavior
and activity of nigrostriatal neurons [3]. Genetic varia-
tion in these proteins, which are responsible for
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ibility to PD.
Decreased COMT activity may result in increased
metabolism of dopamine to neuromelanin that can
enhance the formation of cyototoxic radicals contributing
to neuronal degeneration [4]. As the A allele of COMT
rs4680 is associated with low COMT activity of soluble
COMT [5], the A allele of COMT rs4680 may be linked
to an increased risk of PD. It has been suggested that
MAOB inhibition may prevent degeneration of the dopa-
minergic system in PD [6]. It is well-documented that
cigarette smoking is associated with reduced MAOB
activity and confers beneficial effects against PD [7].
Therefore, low MAOB activity may play a preventive role
in PD development. Although the MAOB rs1799836
polymorphism is a synonymous substitution, this single
nucleotide polymorphism (SNP) is associated with vary-
ing enzyme activity. In fact, synonymous SNPs can cause
inactivation of the native splicing donor site, which
results in a premature stop codon or exon skipping,
yielding a shorter mRNA [8]. The shorter mRNA results
in a truncated protein that is likely rapidly degraded or
functionally inactive [9]. As the G allele of MAOB
rs1799836 polymorphism is associated with lower activity
of brain MAOB activity [10], the G allele may be involved
in PD susceptibility (protective). The DRD2 rs1800497 T
allele (formerly DRD2 TaqI A1) showed reduced DRD2
density in the postmortem brain [11], decreased receptor
binding in positron emission tomography in vivo [12]
and reduction of dopaminergic activity in the CNS [13].
However, the impact of DRD2 rs1800497 on D2 receptor
density has recently been questioned [14]. The functional
significance of DRD2 rs1800497 is not clear at this time,
and there may be linkage disequilibrium between the
other polymorphisms. The DRD4 rs1800955 SNP is
thought to influence promoter activity with the T allele
exhibiting a 40% reduction in promoter activity relative
to the C allele in vitro [15]. As the T allele of DRD4
rs1800955 is considered to be involved in defects in
dopaminergic neurotransmission, the T allele may play a
deleterious role in PD development.
Studying gene-environment interactions in relation to
PD risk may be valuable because positive findings would
clearly implicate disease-causing exposures, clarify PD
etiology, and elucidate environmental modifications for
disease prevention. This study aimed to determine the
impact of polymorphisms involved in dopaminergic neu-
rotransmission on PD risk alone or in combination with
smoking in a Japanese population.
Methods
Study subjects
PD patients were recruited at three university hospitals
and one national hospital in Fukuoka Prefecture, a
metropolitan area of Kyushu Island in southern Japan,
and in three university hospitals, three national hospitals
and one municipal hospital in Osaka, Kyoto, and
Wakayama Prefectures. Eligible (prevalent) cases were
patients who were within 6 years of the onset of PD and
who presented at one of the 11 collaborating hospitals
between April 1, 2006 and March 31, 2008. The mean
duration (± SD) of PD was 38.8 (16.7) months. The
mean age of onset (± SD) was 65.76 (± 8.82) years.
There were no patients with juvenile PD. During the
same period, hospital controls, without a previous diag-
nosis of a neurodegenerative or malignant disease, were
recruited from departments other than the department
of neurology because hospital controls are more moti-
vated and are more easily accessible for obtaining DNA
samples. Controls were not, individually or in larger
groups, matched to cases. Details of the study subjects
have been documented elsewhere [13].
Six hundred and eleven subjects (240 PD patients and
371 controls) agreed to donate buccal samples. Data on
smoking and pesticide use were insufficient for two
cases and one control. In total, 238 cases and 369 con-
trols were enrolled in this study. The ethics committees
of the eleven collaborating universities/hospitals
approved the research protocol, and all subjects signed
informed consent.
Genetic analysis
Genomic DNA was extracted from buccal samples.
Genetic determinations were blinded to PD status. Taq-
Man SNP Genotyping Assays (ABI) were used for the
following (gene, SNP, assay ID): COMT, rs4680,
C_25746809_50; MAOB, rs1799836, C_8878790_10;
DRD2, rs1800497, C_7486676_10; DRD4, rs1800955,
C_7470700_30.
Statistical analysis
To test for associations between SNPs and PD, we
defined the ancestral allele using the National Center
for Biotechnology Information SNP database as the
major allele. We assessed Hardy-Weinberg equilibrium
(HWE) via a goodness-of-fit c
2 test (Pearson) to com-
pare the observed and expected genotype frequencies
among controls. Based on the results from functional
studies (SNPs other than DRD2 rs1800497) and our
results of associations between SNPs and PD, we desig-
nated the genotype presumed to increase the risk of PD
as the “at-risk” genotype. The trend of association was
assessed by a logistic regression model assigning ordinal
scores to the levels of the independent variable. As
MAOB is located on the X chromosome (Xp11.23), the
genotypes were assessed separately in men and women.
Although men are in a hemizygous state, the genotypes
of MAOB rs1799836 for men were coded as
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categories (0-2 and 3, 4, 5, 6, and 7+). Alternatively, all
“at-risk” alleles were classified into four categories (0-3
a n d4 ,5 ,6+ ) .U n c o n d i t i o n a ll o g i s t i cr e g r e s s i o nw a s
used to compute the odds ratios (ORs) and their 95%
confidence intervals (CIs), with adjustments for potential
confounders. The potential confounders included age
(continuous variable), sex (male/female), region of resi-
dence (Fukuoka/Kinki), smoking status (ever/never),
alcohol consumption [long-term consumption of alco-
holic beverages (continuing consuming for ≥49 years,
which is a cutoff point at the 90th percentile of con-
trols)/short-term consumption of alcoholic beverages
(continuing consuming for < 49 years)] and pesticide,
herbicide or fungicide exposure (ever/never). Modeling
different mechanisms of action of a particular allele was
conducted by grouping individuals with one or two par-
ticular genotypes regarding the chosen model (dominant
model: scored as 1 for heterozygous and homozygous of
the possible risk allele for PD and 0 otherwise; recessive
model: scored as 1 for homozygous of the possible risk
allele for PD and 0 otherwise). The interaction between
SNPs and cigarette smoking on the risk of PD was sta-
tistically evaluated based on the likelihood test, compar-
ing the models with and without a term for interaction
(multiplicative scale).
All statistical analyses were implemented in STATA
Version 10.1. All P values were two-sided, with those
less than 0.05 considered statistically significant.
Results
The distributions of selected characteristics among sub-
jects are summarized in Table 1. Two hundred and
thirty-eight patients with PD and 369 controls were
enrolled in the study. The sex ratio, the prevalence of
first degree family history of PD and the region of resi-
dence did not differ significantly between cases and con-
trols. Compared with control subjects, cases were more
likely to be older (P = 0.007) and report long-term alco-
hol consumption (P = 0.041). PD patients were less
likely to report a history of smoking compared to the
control subjects (P < 0.0001). Unexpectedly, the PD
patients tended to have less frequent home or occupa-
tional pesticide exposure.
The distributions of polymorphisms involved in
dopaminergic neurotransmission among cases and con-
trols are shown in Table 2. Four SNPs did not deviate
from HWE in controls (PHWE = 0.077 for COMT
rs4680, PHWE = 0.443 for MAOB rs1799836 among
women, PHWE = 0.111 for DRD2 rs1800497, PHWE =
0.083 for DRD4 rs1800955). As MAOB is located on
the X chromosome, rs1799836 among men (no hetero-
zygotes) and women combined deviated from HWE.
There were nonsignificant differences in genotypic
frequencies between case and control subjects for all
of the polymorphisms (P = 0.106 - 0.460). The AA
genotype of COMT rs4680 was marginally associated
with an increased risk of PD compared with the GG
genotype (OR = 1.86, 95% CI = 0.98 - 3.50). There was
a significant trend in increasing risk with the number
of the A alleles of COMT rs4680 (Ptrend = 0.044). A
dominant effect of the A allele on PD risk was sug-
gested. Subjects with the AA genotype had a signifi-
cantly increased risk of PD compared with those with
at least one G allele (adjusted OR = 1.70, 95% CI =
1.12 - 2.58). There was a significant trend in decreas-
ing risk with the number of the G alleles of MAOB
rs1799836 (Ptrend = 0.016). A recessive effect of the A
allele of MAOB rs1799836 on PD risk was suggested.
The C allele of DRD2 rs1800497 was associated with
an increased risk of PD and appeared to act in a reces-
sive mode in this study. Similarly, the T allele of DRD4
Table 1 Selected characteristics of Parkinson’s disease
cases and controls
Characteristics Cases
(n = 238)
Controls (n =
369)
P
Age, year (95% CI) 68.5
(67.4 - 69.6)
66.6
(65.7 - 67.4)
0.007
Sex, n (%)
Male 91 (38.2) 140 (38.0)
Female 147 (61.8) 228 (62.0) 0.96
First degree family
history of PD, n (%) 11 (4.62) 12 (3.25) 0.39
Smoking status, n (%)
Current smoker 7 (2.94) 50 (13.6)
Former smoker 57 (24.0) 97 (26.3)
Non-smoker 174 (73.1) 222 (60.2) < 0.0001
Consumption of alcoholic
beverages, n (%)*
Short-term 195 (81.9) 320 (87.9)
Long-term 43 (18.1) 44 (12.1) 0.041
Home pesticide use, n (%)
Yes 117 (49.2) 202 (54.7)
No 121 (50.8) 167 (45.3) 0.18
Occupational pesticide use, n
(%)
Yes 20 (8.4) 33 (8.9)
No 218 (91.6) 336 (91.1) 0.82
Either home or occupational
pesticide use, n (%)
Yes 122 (51.3) 210 (56.9)
No 116 (48.7) 159 (43.1) 0.17
Region of residence, n (%)
Fukuoka 89 (37.4) 154 (41.7)
Kinki 149 (62.6) 215 (58.3) 0.29
95% CI, 95% confidence interval
Five cases were missing.
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appeared to behave in a dominant fashion.
We assessed interactions between polymorphisms
involved in dopaminergic neurotransmission and smok-
ing (Table 3). To achieve adequate statistical power, cur-
rent and former smokers were combined (ever smokers).
The OR of a history of smoking was 0.40 (95% CI =
0.25 - 0.64) after adjustment for age, sex, first degree
family history of PD, region, alcohol consumption and
pesticide use (data not shown). As shown in Table 3,
non-smokers with at least one A allele of COMT rs4680
(adjusted OR = 3.97, 95% CI = 2.13 - 7.41) had a higher
risk of PD than those with the GG genotype (adjusted
OR = 3.70, 95% CI = 1.95 - 7.02), relative to ever smo-
kers with the GG (non-risk) genotype (reference). Ever
smokers with the GA and AA genotypes combined had
a significantly increased risk of PD (adjusted OR = 2.19,
95% CI = 1.17 - 4.10). Evidence of interaction between
the COMT rs4680 genotypes and smoking was sug-
gested (P = 0.061). Similarly, non-smokers with the “at-
risk” AA genotype of MAOB rs1799836 (adjusted OR =
5.74, 95% CI = 2.16 - 15.2) had a higher risk of PD than
those with the AG and GG genotypes combined
(adjusted OR = 3.68, 95% CI = 1.30 - 10.4), relative to
Table 2 Associations of polymorphisms involved in dopaminergic neurotransmission and Parkinson’s disease
Polymorphism Cases (%)
(n = 238)
Controls (%)
(n = 369)
P Adjusted* OR
(95% CI)
COMT rs4680
GG (ancestral) 98 (41.2) 179 (48.5) 1.0
GA 116 (48.7) 166 (45.0) 1.26 (0.88 - 1.79)
AA 24 (10.1) 24 (6.5) 0.106 1.86 (0.98 - 3.50)
PHWE = 0.077 Ptrend = 0.044
GA + AA vs. GG 140 (58.8) 190 (51.4) 1.33 (0.95 - 1.87)
MAOB rs1799836
AA (A) (ancestral) 192 (80.7) 273 (74.0) 1.0
AG 34 (14.3) 68 (18.4) 0.61 (0.37 - 0.99)
GG (G) 12 (5.0) 28 (7.6) 0.55 (0.26 - 1.16)
PHWE < 0.0001 0.154 Ptrend = 0.016
AA (A) vs. AG +
GG (G)
1.70 (1.12 - 2.58)
Female
AA (ancestral) 110 (74.8) 156 (68.1) 1.0
AG 34 (23.1) 68 (29.7) 0.60 (0.36 - 0.99)
GG 3 (2.13) 5 (2.18) 0.90 (0.21 - 3.97)
PHWE = 0.443 0.368 Ptrend = 0.084
Male
A 82 (90.1) 117 (83.7) 1.0
G 9 (9.89) 23 (16.3) 0.166 0.45 (0.19 - 1.09)
DRD2 rs1800497
TT (ancestral) 29 (12.2) 52 (14.1) 1.0
TC 117 (49.2) 192 (52.0) 1.04 (0.61 - 1.77)
CC 92 (38.7) 125 (33.9) 0.460 1.32 (0.77 - 2.28)
PHWE = 0.111 Ptrend = 0.204
CC vs. TC + TT 1.28 (0.90 - 1.82)
DRD4 rs1800955**
TT (ancestral) 81 (34.0) 136 (37.0) 1.0
TC 122 (51.3) 162 (44.0) 1.23 (0.85 - 1.79)
CC 35 (14.7) 70 (19.0) 0.173 0.88 (0.54 - 1.47)
PHWE = 0.083 Ptrend = 0.928
TT + TC vs. CC 1.27 (0.80-2.00)
*Adjusted for age, sex, first degree family history of PD, region, smoking status, drinking status and pesticide exposure.
**One control was missing.
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Smokers with the AA genotype presented a nonsignifi-
cantly increased risk of PD (adjusted OR = 2.39, 95% CI
= 0.91 - 6.27). Interaction between the MAOB
rs1799836 genotypes and smoking was far from signifi-
cant. As for the DRD2 rs1800497 and DRD4 rs1800955
SNPs, the significantly high ORs were attributed largely
to the effect of non-smoking. The interaction measure
between smoking and either DRD2 rs1800497 or DRD4
rs1800955 did not reach statistical significance.
There were no polymorphism-polymorphism interac-
tions in any possible combination (data not shown).
We examined the cumulative effect of putative “at-
risk” alleles of four SNPs involved in dopaminergic neu-
rotransmission on PD risk (Table 4). Increasing num-
bers of putative “at-risk” alleles increased PD risk in a
dose dependent manner (Ptrend =0 . 0 0 7 ) .T h er i s kw a s
more than doubled in subjects with seven or eight puta-
tive “at-risk” alleles (adjusted OR = 2.66, 95% CI = 1.03
- 6.88), compared to those with one or two putative “at-
risk” alleles. Alternatively, for carriers with more than
five putative “at- risk” alleles, PD risk was increased ~2-
fold (OR = 1.80, 95% CI = 1.07 - 3.05), compared with
carriers with less than or equal to three putative “at-
risk” alleles.
Discussion
The polymorphisms involved in dopaminergic neuro-
transmission such as COMT rs4680, MAOB rs1799836,
DRD2 rs1800497 and DRD4 rs1800955 were determined
in a total of 607 Japanese subjects (238 PD cases and
369 controls). As compared with the GG genotype of
Table 3 Interaction between smoking and polymorphisms involved in dopaminergic neurotransmission in Parkinson’s
disease
Polymorphism Genotype Non-smokers Ever smokers Pinteaction
Cases/controls Adjusted OR*
(95% CI)
Cases/controls Adjusted OR*
(95% CI)
COMT No risk† (GG) 77/103 3.70 (1.95 - 7.02) 21/76 1.0 (reference) 0.061
rs4680 At-risk† (GA + AA) 97/119 3.97 (2.13 - 7.41) 43/71 2.19 (1.17 - 4.10)
MAOB No risk‡ [GG (G) + AG] 40/70 3.68 (1.30 - 10.4) 6/26 1.0 (reference) 0.434
rs1799836 At- risk‡ [AA (A)] 134/152 5.74 (2.16 - 15.2) 58/121 2.39 (0.91 - 6.27)
DRD2 No risk‡ (TC + TT) 108/153 2.32 (1.34 - 3.99) 38/91 1.0 (reference)
rs1800497 At- risk‡ (CC) 66/69 3.16 (1.75 - 5.70) 26/56 1.12 (0.61 - 2.08) 0.608
DRD4 No risk† (CC) 25/37 2.98 (1.18 - 7.56) 10/33 1.0 (reference)
rs1800955** At- risk† (TT + TC) 149/184 3.50 (1.57 - 7.80) 54/114 1.48 (0.67 - 3.28) 0.637
*Adjusted for age, sex, first degree family history of PD, region, drinking status and pesticide exposure.
**One control was missing.
† Based on the dominant model.
‡ Based on the recessive model.
Table 4 Relationship of total number of “at-risk” genotypes of polymorphisms involved in dopaminergic
neurotransmission to Parkinson’s disease
Number of “at-risk"*
alleles
Subjects, n (%) Adjusted† OR (95% CI)
Cases
(n = 238)
Controls**
(n = 368)
0 0 (0.0) 0 (0.0) - - -
1 2 (0.84) 6 (1.63) 1.0 (reference) 1.0
2 8 (3.36) 16 (4.35) 1.41 (0.22 - 9.06) (reference) 1.0 (reference)
3 25 (10.5) 46 (12.5) 1.59 (0.29 - 8.74) 1.23 (0.49 - 3.09)
4 51 (21.4) 100 (27.2) 1.65 (0.31 - 8.78) 1.28 (0.54 - 2.99) 1.10 (0.64 - 1.90)
5 73 (30.7) 107 (29.1) 2.13 (0.41 - 11.2) 1.64 (0.71 - 3.79) 1.42 (0.85 - 2.39)
6 51 (21.4) 65 (17.7) 2.39 (0.45 - 12.7) 1.84 (0.78 - 4.36)
7 25 (10.5) 26 (7.07) 3.47 (0.62 - 19.4) 2.66 1.80 (1.07 - 3.05)
8 3 (1.26) 2 (0.54) 3.25 (0.28 - 37.8) (1.03 - 6.88)
Ptrend= 0.007 Ptrend= 0.007 Ptrend= 0.012
* Based on our results, we designated the allele that is presumed to increase the risk of PD as the “at-risk” allele.
**One control was missing.
†Adjusted for age, sex, first degree family history of PD, region, smoking status, drinking status and pesticide exposure.
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ciated with an increased risk of PD. The AA genotype
of COMT rs4680 has been reported to be a genetic risk
factor for PD in Japanese populations [16,17] but the
studies among ethnic populations other than Japanese
failed to confirm any significant association [5,18-25].
This ethnic difference might be partly due to the differ-
ence in the allelic frequency of COMT rs4680. Accord-
ing to the HapMap SNP database [26], the A allele
frequency is more common among Caucasians (51.7%)
and less common among Japanese (23.3%), Han Chinese
(25.6%) and Yorubas (a West African ethnic group,
29.2%). The frequency of the A allele in this study
(29.0%) was somewhat higher than that of the HapMap
SNP database but similar to that of other Japanese
populations (28.8% and 31.1%) [16,17]. Generally, the
low frequency of the “at risk” allele reduces the statisti-
cal power. As the prevalence of the A allele was lower
in Japanese than in Caucasians, this is not the case.
Given the lower frequency of the A allele in Japanese
subjects, if this allele is associated with an increased risk
of PD, then the prevalence of PD would be lower
among Japanese than Caucasians. In fact, the prevalence
of PD is generally lower in Asian and African-American
populations than in Caucasian populations [27,28]. The
reason why Japanese studies found a significant associa-
tion between COMT rs4680 and PD risk is not clear.
The ethnic difference may reflect different gene-environ-
ment interactions, gene-gene interactions, or different
linkages to the polymorphisms determining PD risk.
As compared with individuals with at least one G
allele of MAOB rs1799836, those with the AA genotype
had a significantly increased risk of PD. A number of
studies have examined MAOB rs1799836 and PD risk
with conflicting results. Some studies reported that the
G allele of MAOB rs1799836 was significantly associated
with an increased risk of PD [22,29,30]. Similarly, the
presence of the G allele was associated with a modest
increased risk of PD [22,25,31]. On the contrary, a sig-
nificant association between the A allele of MAOB
rs179986 and an increased PD risk was observed [32].
Other studies found no association between this poly-
morphism and PD risk [23,24,33-36]. A meta-analysis
based on six studies published before November 1999
reported that there was no significant association of
MAOB rs1799836 with PD [37]. Each population may
have its own set of environmental and genetic factors
that contribute to PD risk. The lack of replication can
in part be accounted for as the role of MAOB rs179986
on PD risk differs with environmental factors such as
smoking.
The DRD2 rs1800497 and DRD4 rs1800955 SNPs
were not associated with PD risk in this study. No sig-
nificant association of DRD2 rs1800497 and PD risk has
been reported in different populations [30,36,38-40].
However, two studies of Caucasians found that the T
allele of DRD2 rs1800497 was associated with a signifi-
cantly increased risk of PD [41,42]. As the conflicting
results may be attributed to linkage disequilibrium (LD)
between the other polymorphisms, there is a possibility
that other polymorphisms such as -141 Ins/Del
(rs1799732), Ser311Cys (rs1801028), Taq IB (rs1079597)
and C957T (rs6277), which may be in LD with
rs1800497, may play a causative role in PD develop-
ment. The differences in LD would be observed among
different populations [43] and different historical stages
of the same population [44]. Therefore, it is more likely
that the ethnic differences of the association between
DRD2 rs1800497and PD exist. As reproducibility of the
results is important in genetic association studies, addi-
tional studies with a large sample size are needed to
clarify the pivotal role of DRD2 rs1800497 in PD devel-
opment. Furthermore, the association of the T allele of
DRD2 rs1800497 with receptor availability was not
always replicated. Future mechanistic studies are needed
to verify the functional significance of different DRD2
rs1800497 alleles. To the best of our knowledge, no stu-
dies on the association between DRD4 rs1800955 and
PD have been previously reported. PD risk associated
with the 48 bp tandem repeat polymorphism of DRD4
at the third exon, which may also be functional, has
been evaluated, and one [45] of four studies [45-48]
found a significant association. This tandem repeat poly-
morphism is probably not the main determinant in
developing PD. Again, testing replication in different
populations is an important step. Additional studies are
warranted to corroborate the null association among
Japanese samples suggested in the present study.
It is widely accepted that PD development requires
environmental factors acting on a genetically predis-
posed individual. A gene-environment interaction was
suggested, with the GA and AA combined genotype of
COMT rs4680 and non-smoking conferring significantly
higher risk (OR = 3.97, 95% CI = 2.13 - 7.41), compared
with the GG genotype and a history of smoking (P for
interaction = 0.061). In other words, the impact of the
combined genotype of GA and AA on PD risk was mar-
ginally different between ever smokers (2.19) and non-
smokers (3.97/3.70 = 1.07). In contrast to our results,
two studies have reported no interaction between cigar-
ette smoking and COMT rs4680 in relation to PD risk
[23,25]. Our results suggest that interaction between
COMT rs4680 and smoking is likely to vary in different
races. Additional epidemiological studies are warranted
to determine the smoking-COMT polymorphism inter-
action. There were no interactions between MAOB
rs1799836, DRD2 rs1800497 or DRD4 rs1800955 poly-
morphisms and smoking. Conflicting results regarding
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have been reported. MAOB rs1799836 modified the
association between PD risk and smoking [31,49]. A sig-
nificant interaction was observed in men but not in
women [50]. Several studies, including the studies with
the same data or overlapping data by the overlapping
authors [23,39], also reported no interaction between
MAOB rs1799836 and smoking in PD risk [23,35,36,39].
Other environmental factors may reduce MAOB and
such phenotypic determinants may vary across popula-
tions. Given the possibility of environmental effects on
MAOB activity, further work on interactions between
the MAOB polymorphism and smoking is needed.
There was no interaction between smoking and DRD2
rs180049 in two studies [36,39]. No studies examining
the interactions between smoking and the DRD4
rs1800955 in PD have been published to date. Ethnicity
might also play a role when studying the role of genetic
factors in the association between smoking and PD.
Accumulation of multiple “at-risk” alleles markedly
increased the risk of PD in a dose dependent manner,
although each “at-risk” allele was associated with a small
increase in risk (Table 4). Thus, individuals may have
several nonsignificant “at-risk” genotypes” whose com-
bined effect results in a high-risk. Compared with
known nongenetic risk factors, smoking (1/0.40 = 2.50)
and a combination of “at-risk” alleles (2.66, seven or
eight “at-risk” alleles vs, less than four “at-risk” alleles)
provided the same impact in PD risk prediction. Our
study therefore suggests that the combined effect of
multiple variant alleles may be more important than the
investigation of a SNP in modulating PD risk although
“at-risk” allele combinations are rare in the general
population. However, although an “at-risk” allele (geno-
type) may confer a small individual risk, this small
increase in risk translates to a large number of excess
PD cases in the population. Therefore, the polymorph-
isms, even those not significantly associated with PD,
should be considered an important public health issue.
One strength of our study is that cases were identified
according to strict diagnostic criteria, and thus the pos-
sibility of misclassification of PD is negligible. Several
limitations of the study also warrant mention. Our study
may have included a bias due to the self-reporting of
smoking habits. However, discrepancies between self-
reported smoking habits and biochemical verification
are minimal among the general population [51,52].
Another problem with case-control studies is recall bias.
As risk factors for PD are poorly characterized, study
subjects have few systematic preconceived ideas regard-
ing their disease etiology. Any recall bias was likely to
be non-differential given the many pesticides reported,
the complex temporal pattern of their use, and the fact
that subjects were not informed of the study hypotheses.
Conclusions
O u rr e s u l t ss u g g e s tt h a tt h eMAOB rs1799836 played an
important role in PD susceptibility in our Japanese popula-
tion. To the best of our knowledge, this is the first report
on the relationship between DRD4 rs1800955 with PD.
Our study provides evidence of the interaction between
COMT rs4680 polymorphisms and smoking. The previous
studies have failed to confirm any significant association
between PD and rs1799836/rs4680 [53], however. Replica-
tion of findings is very important before any causal infer-
ence can be drawn. In order to confirm our findings,
consortia of investigators working on PD may need to be
established. Future studies involving larger control and
case populations and better pesticide exposure histories
will undoubtedly lead to a more thorough understanding
of the role of the polymorphisms involved in dopaminergic
neurotransmission in PD development.
Appendix
Other members of the Fukuoka Kinki Parkinson’sD i s -
ease Study Group are as follows: Yasuhiko Baba and
Tomonori Kobayashi (Department of Neurology, Faculty
of Medicine, Fukuoka University); Hideyuki Sawada, Eiji
Mizuta and Nagako Murase (Clinical Research Institute
and Department of Neurology, Utano National Hospi-
tal); Tsuyoshi Tsutada and Takami Miki (Department of
Geriatrics and Neurology, Osaka City University Gradu-
ate School of Medicine); Jun-ichi Kira (Department of
Neurology, Neurological Institute, Graduate School of
Medical Sciences, Kyushu University); Tameko Kihira
and Tomoyoshi Kondo (Department of Neurology,
Wakayama Medical University); Hidekazu Tomimoto
(Department of Neurology, Kyoto University Graduate
School of Medicine); Takayuki Taniwaki (Division of
Respirology, Neurology, and Rheumatology, Department
of Medicine, Kurume University School of Medicine);
Hiroshi Sugiyama and Sonoyo Yoshida (Department of
Neurology, Kyoto-Minami National Hospital); Harutoshi
Fujimura and Tomoko Saito (Department of Neurology,
Toneyama National Hospital); Kyoko Saida and Junko
Fujitake (Department of Neurology, Kyoto City Hospi-
tal); Naoki Fujii (Department of Neurology, Neuro-Mus-
cular Center, National Omuta Hospital); Masatoshi
Naito and Jun Arimizu (Department of Orthopaedic
Surgery, Faculty of Medicine, Fukuoka University);
Takashi Nakagawa, Hirofumi Harada, and Takayuki
Sueta (Department of Otorhinolaryngology, Faculty of
Medicine, Fukuoka University); Toshihiro Kikuta and
George Umemoto (Department of Oral and Maxillofa-
cial Surgery, Faculty of Medicine, Fukuoka University);
Eiichi Uchio and Hironori Migita (Department of
Ophthalmology, Faculty of Medicine, Fukuoka Univer-
sity); Kenichi Kazuki, Yoichi Ito, and Hiroyoshi Iwaki
(Department of Orthopaedic Surgery, Osaka City
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Page 7 of 9University Graduate School of Medicine); Kunihiko Sir-
aki and Shinsuke Ataka (Department of Ophthalmology
and Visual Sciences, Osaka City University Graduate
School of Medicine); Hideo Yamane and Rie Tochino
(Department of Otolaryngology and Head and Neck
Surgery, Osaka City University Graduate School of Med-
icine); Teruichi Harada (Department of Plastic and
Reconstructive Surgery, Osaka City University Graduate
School of Medicine); Yasushi Iwashita, Motoyuki Shi-
mizu, Kenji Seki, and Keiji Ando (Department of Ortho-
pedic Surgery, Utano National Hospital).
List of abbreviations
CI: confidence interval; CNS: central nervous system; COMT: catechol-O-
methyltransferase; DRD2: dopamine receptor D2; DRD4: dopamine receptor
D4; HWE: Hardy-Weinberg equilibrium; MAOB: monoamine oxidase B, OR,
odds ratio; PD: Parkinson’s disease; SNP: single nucleotide polymorphism.
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